Research Article

The Effectiveness of Zolpidem in Improving Consciousness in Patients with Acute Brain Injury

Abstract

Background: Disorders of consciousness, including the vegetative state (VS) and the minimally conscious state (MCS) following brain damage and various complications for the patient, also have economic and social consequences. However, there is still no definitive or effective treatment for this condition. However, there is still no definitive or effective treatment for this condition. Therefore, this study aims to investigate the effectiveness of zolpidem in improving consciousness in patients with acute brain injury.
Methods: The present quasi-experimental study was performed from 2020 to 2021 after obtaining the necessary permissions from Zahedan University of Medical Sciences, Iran. Eighty patients with acute brain injury who met the study inclusion criteria were recruited and randomized into zolpidem and placebo groups. In the zolpidem group, 10 mg zolpidem tablets were gavage twice daily. In the placebo group, a placebo tablet with the same appearance as zolpidem was gavage twice daily for 14 days. The consciousness level of patients was measured daily until the outcome (ICU discharge or expiration) was established. Eventually, a comparative data analysis was conducted to determine zolpidem's efficacy in enhancing consciousness, reducing mechanical ventilation duration, and improving patient outcomes.
Results: The mean GCS score in the zolpidem group was 6.1±2.4 on admission and 11.6±3.8 at the end of the study, compared to 5.9±1.7 on admission and 11.3±2.8 at the end of the study, for the placebo group (p=0.154 and p=0.211, respectively). The mean duration of mechanical ventilation was 24.41±9.14 days in the zolpidem group and 23.16±10.72 days in the placebo group (P=0.529). Twenty-eight patients in the zolpidem group were discharged from ICU, and 12 expired. For the placebo group, 26 patients were discharged from ICU, while 14 were expired (p=0.87). No statistically significant difference was found in any of the measured variables between the two groups.
Conclusion: The results have shown that zolpidem administration had no statistically significant effect on improving the level of consciousness and reducing mechanical ventilation duration and clinical outcomes in acute brain injury patients.

[1] Khalili H, Rakhsha A, Ghaedian T, Niakan A, Masoudi N. Application of brain perfusion SPECT in the evaluation of response to zolpidem therapy in consciousness disorder due to traumatic brain injury. Indian J Nucl Med. 2020; 35(4):315-20.
[2] Whyte J, Myers R. Incidence of clinically significant responses to zolpidem among patients with disorders of consciousness: a preliminary placebo controlled trial. Am J Phys Med Rehabil. 2009; 88(5):410-8.
[3] Passler MA, Riggs RV. Positive outcomes in traumatic brain injury-vegetative state: patients treated with bromocriptine. Arch Phys Med Rehabil. 2001; 82(3):311-5.
[4] Giacino JT, Zasler ND. Outcome after severe traumatic brain injury: coma, the vegetative state, and the minimally responsive state. The Journal of Head Trauma Rehabilitation. 1995;10(1):41-56
[5] Yamamoto T, Katayama Y, Kano T, Kobayashi K, Oshima H, Fukaya C. Deep brain stimulation for the treatment of parkinsonian, essential, and poststroke tremor: a suitable stimulation method and changes in effective stimulation intensity. J Neurosurg. 2004;101(2):201-9.
[6] Yamamoto T, Katayama Y, Kobayashi K, Oshima H, Fukaya C, Tsubokawa T. Deep brain stimulation for the treatment of vegetative state. Eur J Neurosci. 2010; 32(7):1145-51.
[7] Lozano AM, Lipsman N, Bergman H, Brown P, Chabardes S, Chang JW, et al. Deep brain stimulation: current challenges and future directions. Nat Rev Neurol. 2019; 15(3):148-60.
[8] Ciurleo R, Bramanti P, Calabrò RS. Pharmacotherapy for Disorders of Consciousness: Are ‘Awakening’ Drugs Really a Possibility? Drugs. 2013; 73(17):1849-62.
[9] Gosseries O, Charland-Verville V, Thonnard M, Bodart O, Laureys S, Demertzi A. Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness. Curr Pharm Des. 2014; 20(26):4167-84.
[10] Cohen SI, Duong TT. Increased arousal in a patient with anoxic brain injury after administration of zolpidem. Am J Phys Med Rehabil. 2008; 87(3):229-31.
[11] Pistoia F, Mura E, Govoni S, Fini M, Sarà M. Awakenings and Awareness Recovery in Disorders of Consciousness. CNS Drugs. 2010; 24(8):625-38.
[12] Hall SD, Yamawaki N, Fisher AE, Clauss RP, Woodhall GL, Stanford IM. GABA (A) alpha-1 subunit mediated desynchronization of elevated low frequency oscillations alleviates specific dysfunction in stroke–a case report. Clinical Neurophysiology. 2010; 121(4):549-55.
[13] Sanna E, Busonero F, Talani G, Carta M, Massa F, Peis M, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABAA receptor subtypes. Eur J Pharmacol. 2002; 451(2):103-10.
[14] Noormandi A, Shahrokhi M, Khalili H. Potential benefits of zolpidem in disorders of consciousness. Expert Rev Clin Pharmacol. 2017;10(9):983-92.
[15] Bruno M-A, Vanhaudenhuyse A, Thibaut A, Moonen G, Laureys S. From unresponsive wakefulness to minimally conscious PLUS and functional locked-in syndromes: recent advances in our understanding of disorders of consciousness. J Neurol. 2011; 258(7):1373-84.
[16] Singh R, McDonald C, Dawson K, Lewis S, Pringle A-M, Smith S, et al. Zolpidem in a minimally conscious state. Brain Injury. 2008; 22(1):103-6.
[17] Bomalaski MN, Claflin ES, Townsend W, Peterson MD. Zolpidem for the Treatment of Neurologic Disorders: A Systematic Review. JAMA Neurol. 2017; 74(9):1130-9.
[18] Dixon CL, Harrison NL, Lynch JW, Keramidas A. Zolpidem and eszopiclone prime α1β2γ2 GABAA receptors for longer duration of activity. Br J Pharmacol. 2015; 172(14):3522-36.
[19] Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet. 1995; 29(3):142-53.
[20] Clauss RP. Neurotransmitters in Coma, Vegetative and Minimally Conscious States, pharmacological interventions. Med Hypotheses. 2010;75(3):287-90.
[21] Clauss RP. Neurotransmitters in disorders of consciousness and brain damage. Medical Hypotheses. 2011; 77(2):209-13.
[22] Whyte J, Rajan R, Rosenbaum A, Katz D, Kalmar K, Seel R, et al. Zolpidem and restoration of consciousness. Am J Phys Med Rehabil. 2014; 93(2):101-13.
[23] Machado C, Estévez M, Rodríguez R, Pérez-Nellar J, Chinchilla M, DeFina P, et al. Zolpidem arousing effect in persistent vegetative state patients: autonomic, EEG and behavioral assessment. Curr Pharm Des. 2014; 20(26):4185-202.
[24] Thonnard M, Gosseries O, Demertzi A, Lugo Z, Vanhaudenhuyse A, Bruno MA, et al. Effect of zolpidem in chronic disorders of consciousness: a prospective open-label study. Funct Neurol. 2013; 28(4):259-64.
Files
IssueVol 10 No 1 (2024): Winter QRcode
SectionResearch Article(s)
DOI https://doi.org/10.18502/aacc.v10i1.14766
Keywords
Acute brain injury Glasgow Coma Scale zolpidem Impaired consciousness level
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Rahat Dahmardeh A, Khoshfetrat M, Heidari M, Keykha A. The Effectiveness of Zolpidem in Improving Consciousness in Patients with Acute Brain Injury. Arch Anesth & Crit Care. 2023;10(1):9-14.